Maintained clinical response of infliximab treatment in ankylosing spondylitis: A 6-year long-term study

Infliximab was effective, safe and well-tolerated in patients with ankylosing spondylitis. The clinical response was maintained for a period of 6 years, with high infliximab survival rate, reaching the percentage of 72.5%.